The Role and Impact of Minimal Residual Disease in NSCLC

Abstract

Purpose of Review

There has been a huge development in the assessment of malignancies through liquid biopsies last years, especially for NSCLC, where its use has become part of clinical practice in some settings. We aim to summarize current evidence about minimal residual disease and its use in lung cancer.

Recent Findings

Recent studies using ctDNA in NSCLC but also in other types of cancer found strong correlations between the presence of ctDNA and the risk of disease progression or death after curative intent, despite current technical difficulties in performing this analysis (high sensitivity and specificity required).

Summary

Evaluation of MRD in NSCLC, especially through ctDNA, could be an important point in future trial designs and could permit a more “targeted” adjuvant treatment.

展开阅读全文
我还没有学会写个人说明!
上一篇

肺癌MRD的检测和临床应用共识

下一篇

Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges

你也可能喜欢

发表评论

插入图片
返回顶部

微信扫一扫

微信扫一扫